Massachusetts General Hospital
The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are: * Is sacituzumab govitecan safe for individuals with this type of cancer? * Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.
This is a single-arm, open-label, phase II study evaluating the toxicity and feasibility of sacituzumab govitecan (SG) followed by docetaxel/cyclophosphamide (TC) in patients with high-risk early-stage HR+/HER2- breast cancer. Participants will receive four 21-day cycles of the study treatment, sacituzumab govitecan, and then four 21-day cycles of docetaxel and cyclophosphamide chemotherapy, for a total of eight cycles or 24 weeks. Participants will be followed for up to three years after completing study treatment. It is expected that about 32 people will take part in this research study. Gil…
Inclusion Criteria: * Female or male patients ≥ 18 years of age. * Histologically confirmed diagnosis of invasive breast cancer after completion of definitive surgical management (either mastectomy or lumpectomy) within 3-12 weeks of starting study treatment. * Participants must have biopsy proven hormone receptor positive (HR+) (either/both estrogen receptor (ER) and progesterone receptor (PR) positive) HER2 negative (HER2-), invasive breast cancer. ER, PR, and HER2 positivity will be determined per ASCO/CAP guidelines by institutional (local) assessment, with expression of either the estrog…
Intravenous infusion administered on days 1 and 8 of cycles 1-4 (one cycle is 21 days).
Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).
Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).